Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.

Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA.

Eur Urol Oncol. 2020 Mar 19. pii: S2588-9311(20)30031-6. doi: 10.1016/j.euo.2020.02.006. [Epub ahead of print] Review.

PMID:
32201133
2.

Bias and stereotyping among research and clinical professionals: Perspectives on minority recruitment for oncology clinical trials.

Niranjan SJ, Martin MY, Fouad MN, Vickers SM, Wenzel JA, Cook ED, Konety BR, Durant RW.

Cancer. 2020 Mar 9. doi: 10.1002/cncr.32755. [Epub ahead of print]

PMID:
32147815
3.

Urological infections in the developing world: an increasing problem in developed countries.

Batirel A, Regmi SK, Singh P, Mert A, Konety BR, Kumar R.

World J Urol. 2020 Feb 27. doi: 10.1007/s00345-020-03120-3. [Epub ahead of print]

PMID:
32108257
4.

Understanding Prostate Cancer in Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women: A Review of the Literature.

Rosser BRS, Hunt SL, Capistrant BD, Kohli N, Konety BR, Mitteldorf D, Ross MW, Talley KM, West W.

Curr Sex Health Rep. 2019 Dec;11(4):430-441. doi: 10.1007/s11930-019-00234-7. Epub 2019 Nov 8.

PMID:
31929765
5.

Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Twenty-First Century Edition.

Konety BR.

Urol Clin North Am. 2020 Feb;47(1):xiii. doi: 10.1016/j.ucl.2019.10.001. No abstract available.

PMID:
31757305
6.

Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer.

Sathianathen NJ, Regmi S, Gupta S, Konety BR.

Urol Clin North Am. 2020 Feb;47(1):103-110. doi: 10.1016/j.ucl.2019.09.012. Review.

PMID:
31757293
7.

Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.

Konety BR, Narayan VM, Dinney CPN.

Urol Clin North Am. 2020 Feb;47(1):1-4. doi: 10.1016/j.ucl.2019.09.002. Review.

PMID:
31757292
8.

Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.

Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA Jr, Thompson IM, Parekh DJ.

J Urol. 2020 Mar;203(3):522-529. doi: 10.1097/JU.0000000000000565. Epub 2019 Sep 24.

PMID:
31549935
9.

Skeletal Muscle and Fat Mass Indexes Predict Discharge Disposition after Radical Cystectomy.

Albersheim J, Sathianathen NJ, Zabell J, Renier J, Bailey T, Hanna P, Konety BR, Weight CJ.

J Urol. 2019 Dec;202(6):1143-1149. doi: 10.1097/JU.0000000000000450. Epub 2019 Jul 17. Erratum in: J Urol. 2020 Feb;203(2):425.

PMID:
31483713
10.

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer.

Umbreen S, Banday MM, Jamroze A, Mansini AP, Ganaie AA, Ferrari MG, Maqbool R, Beigh FH, Murugan P, Morrissey C, Corey E, Konety BR, Saleem M.

Mol Cancer Ther. 2019 Nov;18(11):2111-2123. doi: 10.1158/1535-7163.MCT-19-0150. Epub 2019 Aug 29.

PMID:
31467179
11.

A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.

Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR.

Eur Urol Oncol. 2019 Nov;2(6):649-655. doi: 10.1016/j.euo.2019.01.004. Epub 2019 Jan 30.

PMID:
31411985
12.

Studying the impact of comorbidity on post radical cystectomy survival: have we come a full circle?

Regmi SK, Konety BR.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S314-S317. doi: 10.21037/tau.2019.06.06. No abstract available.

13.

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.

Kalapara AA, Nzenza T, Pan HY, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.

BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858. [Epub ahead of print]

PMID:
31260602
14.

Characterization of Novel Murine and Human PDAC Cell Models: Identifying the Role of Intestine Specific Homeobox Gene ISX in Hypoxia and Disease Progression.

Ganaie AA, Parray A, Hussain T, Shabaneh A, Jamroze A, Ferrari MG, Wang L, Liao DJ, Koochekpour S, Nanda S, Wang J, Deng Y, Gradilone SA, Hinchcliffe EH, Konety BR, Saleem M.

Transl Oncol. 2019 Aug;12(8):1056-1071. doi: 10.1016/j.tranon.2019.05.002. Epub 2019 Jun 4.

15.

Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.

Paul K, Sathianathen N, Dahm P, Le C, Konety BR.

J Urol. 2019 Aug;202(2):385-391. doi: 10.1097/JU.0000000000000294. Epub 2019 Jul 8.

PMID:
31074679
16.

Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration.

Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, Shariat SF, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group.

BJU Int. 2019 May 4. doi: 10.1111/bju.14791. [Epub ahead of print]

PMID:
31055865
17.

The Sexual Functioning of Gay and Bisexual Men Following Prostate Cancer Treatment: Results from the Restore Study.

Rosser BRS, Kohli N, Polter EJ, Lesher L, Capistrant BD, Konety BR, Mitteldorf D, West W, Dewitt J, Kilian G.

Arch Sex Behav. 2019 Apr 23. doi: 10.1007/s10508-018-1360-y. [Epub ahead of print]

PMID:
31016492
18.

Adverse impact of malnutrition markers on major abdominopelvic cancer surgery.

Sathianathen NJ, Kwaan M, Lawrentschuk N, Weight CJ, Kim SP, Murphy DG, Moon DA, Konety BR.

ANZ J Surg. 2019 May;89(5):509-514. doi: 10.1111/ans.15129. Epub 2019 Apr 8.

PMID:
30959573
19.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
20.

Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness.

Sathianathen NJ, Fan Y, Jarosek SL, Konety I, Weight CJ, Vinogradov S, Konety BR.

Eur Urol Focus. 2019 Feb 20. pii: S2405-4569(19)30027-6. doi: 10.1016/j.euf.2019.02.007. [Epub ahead of print]

PMID:
30797737
21.

Difference in MRI-guided biopsy cancer detection rates between individual clinicians.

Sathianathen NJ, Warlick CA, Soubra A, Balaji P, Metzger GJ, Spilseth B, Murugan P, Ordonez M, Weight CJ, Konety BR.

Urol Oncol. 2019 May;37(5):299.e1-299.e6. doi: 10.1016/j.urolonc.2019.01.032. Epub 2019 Feb 21.

PMID:
30797649
22.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

BJU Int. 2019 Sep;124(3):370-372. doi: 10.1111/bju.14711. Epub 2019 Mar 20. Review.

PMID:
30763461
23.

Racial Disparities in Surgical Outcomes Among Males Following Major Urologic Cancer Surgery.

Sathianathen NJ, Jarosek SL, Fan Y, Krishna SR, Konety BR.

Am J Prev Med. 2018 Nov;55(5 Suppl 1):S14-S21. doi: 10.1016/j.amepre.2018.05.012.

24.

African American Men's Health: Research, Practice, and Policy.

Shikany JM, Schoenberger YM, Konety BR, Vickers SM.

Am J Prev Med. 2018 Nov;55(5 Suppl 1):S1-S4. doi: 10.1016/j.amepre.2018.07.011. No abstract available.

26.

Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.

Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM.

Eur Urol. 2019 Jun;75(6):910-917. doi: 10.1016/j.eururo.2018.10.055. Epub 2018 Nov 10.

PMID:
30425010
27.

A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy.

Sathianathen NJ, Warlick CA, Weight CJ, Ordonez MA, Spilseth B, Metzger GJ, Murugan P, Konety BR.

BJU Int. 2019 Apr;123(4):612-617. doi: 10.1111/bju.14617. Epub 2018 Dec 1.

PMID:
30417504
28.

Increased Surgical Complications in Smokers Undergoing Radical Cystectomy.

Sathianathen NJ, Weight CJ, Jarosek SL, Konety BR.

Bladder Cancer. 2018 Oct 29;4(4):403-409. doi: 10.3233/BLC-180185.

29.

Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis.

Sathianathen NJ, Butaney M, Weight CJ, Kumar R, Konety BR.

Bladder Cancer. 2018 Oct 29;4(4):353-363. doi: 10.3233/BLC-180179. Review.

30.

Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis.

Sathianathen NJ, Kalapara A, Frydenberg M, Lawrentschuk N, Weight CJ, Parekh D, Konety BR.

J Urol. 2019 Apr;201(4):715-720. doi: 10.1016/j.juro.2018.10.006.

PMID:
30321551
31.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

32.

Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis.

Sathianathen NJ, Butaney M, Bongiorno C, Konety BR, Bolton DM, Lawrentschuk N.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):39-48. doi: 10.1038/s41391-018-0075-4. Epub 2018 Aug 14.

PMID:
30108376
33.

BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models.

Ganaie AA, Beigh FH, Astone M, Ferrari MG, Maqbool R, Umbreen S, Parray AS, Siddique HR, Hussain T, Murugan P, Morrissey C, Koochekpour S, Deng Y, Konety BR, Hoeppner LH, Saleem M.

Clin Cancer Res. 2018 Dec 15;24(24):6421-6432. doi: 10.1158/1078-0432.CCR-18-1394. Epub 2018 Aug 7.

34.

Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder.

Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple KG, Paner GP, Patel MI, Raspollini MR, Lopez-Beltran A, Konety BR.

World J Urol. 2019 Jan;37(1):107-114. doi: 10.1007/s00345-018-2421-5. Epub 2018 Aug 1. Review.

PMID:
30069580
35.

Landmarks in prostate cancer.

Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk N.

Nat Rev Urol. 2018 Oct;15(10):627-642. doi: 10.1038/s41585-018-0060-7. Review.

PMID:
30065357
36.

Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications.

Sathianathen NJ, Konety BR, Soubra A, Metzger GJ, Spilseth B, Murugan P, Weight CJ, Ordonez MA, Warlick CA.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):573-578. doi: 10.1038/s41391-018-0065-6. Epub 2018 Jul 23.

PMID:
30038389
37.

The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.

Sathianathen NJ, Butaney M, Konety BR.

World J Urol. 2019 Jul;37(7):1239-1249. doi: 10.1007/s00345-018-2403-7. Epub 2018 Jul 12.

PMID:
30003375
38.

FDG-PET/CT for Assessing the Response to Neoadjuvant Chemotherapy in Bladder Cancer Patients.

Soubra A, Gencturk M, Froelich J, Balaji P, Gupta S, Jha G, Konety BR.

Clin Genitourin Cancer. 2018 Oct;16(5):360-364. doi: 10.1016/j.clgc.2018.05.008. Epub 2018 May 31.

PMID:
30001845
39.

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.

Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM.

Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6.

PMID:
29976469
40.

Finasteride-Nemesis of More Than 1 Urological Cancer?

Sathianathen NJ, Konety BR.

J Urol. 2018 Oct;200(4):712-713. doi: 10.1016/j.juro.2018.06.027. Epub 2018 Jun 27. No abstract available.

PMID:
29957298
41.

Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches.

Warlick C, Futterer J, Maruf M, George AK, Rastinehad AR, Pinto PA, Bosaily AE, Villers A, Moore CM, Mendhiratta N, Taneja SS, Ukimura O, Konety BR.

World J Urol. 2019 Mar;37(3):419-427. doi: 10.1007/s00345-018-2374-8. Epub 2018 Jun 25. Review.

PMID:
29943220
42.

Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.

Sathianathen NJ, Kuntz KM, Alarid-Escudero F, Lawrentschuk NL, Bolton DM, Murphy DG, Weight CJ, Konety BR.

J Urol. 2018 Dec;200(6):1215-1220. doi: 10.1016/j.juro.2018.06.016. Epub 2018 Jun 12.

PMID:
29906434
43.

Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study.

Sathianathen NJ, Fan Y, Jarosek SL, Lawrentschuk NL, Konety BR.

Urol Oncol. 2018 Jul;36(7):338.e13-338.e17. doi: 10.1016/j.urolonc.2018.03.020. Epub 2018 May 3.

PMID:
29731413
44.

Potential patient harms from misinterpretation of publically reported surgical outcomes.

Sathianathen NJ, Albersheim-Carter J, Labine L, Watson B, Konety BR, Weight CJ.

BJU Int. 2019 Jan;123(1):180-186. doi: 10.1111/bju.14367. Epub 2018 May 22.

45.

Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.

Sathianathen NJ, Risk MC, Konety BR.

Urol Clin North Am. 2018 May;45(2):215-228. doi: 10.1016/j.ucl.2017.12.006. Epub 2018 Feb 21. Review.

PMID:
29650137
46.

3D Printed Organ Models with Physical Properties of Tissue and Integrated Sensors.

Qiu K, Zhao Z, Haghiashtiani G, Guo SZ, He M, Su R, Zhu Z, Bhuiyan DB, Murugan P, Meng F, Park SH, Chu CC, Ogle BM, Saltzman DA, Konety BR, Sweet RM, McAlpine MC.

Adv Mater Technol. 2018 Mar;3(3). pii: 1700235. doi: 10.1002/admt.201700235. Epub 2017 Dec 6.

47.

Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy.

Schomburg JL, Krishna S, Cotter KJ, Soubra A, Rao A, Konety BR.

Urology. 2018 Jun;116:120-124. doi: 10.1016/j.urology.2018.01.052. Epub 2018 Mar 15.

PMID:
29551621
48.

A Simplified Frailty Index to Predict Outcomes After Radical Cystectomy.

Sathianathen NJ, Jarosek S, Lawrentschuk N, Bolton D, Konety BR.

Eur Urol Focus. 2019 Jul;5(4):658-663. doi: 10.1016/j.euf.2017.12.011. Epub 2018 Jan 20.

PMID:
29366857
49.

The current status of immunobased therapies for metastatic renal-cell carcinoma.

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS.

Immunotargets Ther. 2017 Dec 5;6:83-93. doi: 10.2147/ITT.S134850. eCollection 2017. Review.

50.

Magnetic resonance imaging cognitive fusion biopsy - is near enough good enough?

Sathianathen NJ, Christidis D, Konety BR, Lawrentschuk NL.

BJU Int. 2018 Mar;121(3):324-326. doi: 10.1111/bju.14103. Epub 2018 Jan 3. No abstract available.

Supplemental Content

Loading ...
Support Center